Results Literature search and study characteristics After initial database searches and manual screening of the literature, a total of 1848 unique citations were found, and 29 studies ( n = 26985) published between 2016 and 2023 were eventually included
Most of the research on this drug class was conducted in people with Type 2 diabetes, but it has also been shown to contribute to weight loss and can be prescribed for weight management in people without diabetes
A.FawzyM
Press release: Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy in a pill ) at ObesityWeek 2025, including demonstrated reductions in cardiovascular risk factors.* Retrieved from Papatriantafyllou, E., Efthymiou, D., Zoumbaneas, E., et al
Dual-action GLP-1/GIP receptor agonists like Zepbound can also mimic the action of GIP, a hormone that helps regulate blood sugar levels and metabolism
Indeed, you will find plenty of these, in various forms and with different names